Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
and Agios estimating an initial U.S. addressable launch segment of ~4,000 patients within a ~6,000 diagnosed adult population, while management projects a $1 billion global opportunity and expects gradual ramp as payer formulary placement progresses. In the RISE UP Phase 3 sickle cell study, mitapivat met the hemoglobin endpoint (41% of patients =1 g improvement) and showed favorable safety but did not achieve a statistically significant reduction in vaso-occlusive crises, prompting an upcoming Q1 pre-sNDA FDA meeting to shape the regulatory path. Agios outlined a 2026 catalyst calendar for its pyruvate kinase franchise, including tebapivat readouts (Phase 2b MDS in H1 2026 and sickle cell top-line in H2 2026) and Phase 1 healthy-volunteer data for AG-236 (TMPRSS6 siRNA) expected in 2026. Interested in Agios Pharmaceuticals, Inc.? Here are five stocks we like better. Agios Pharmaceuticals (NASDAQ:AGIO) executives highlighted multiple upcoming clinical and regulatory milestones
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIOPR Newswire
- Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]Yahoo! Finance
- Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab EmiratesGlobeNewswire
- Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- AGIO's page on the SEC website